Johnson & Johnson China Announces Departure of Key Executive Alex He Amid Strategic Restructuring

(Source: Yidu Pharma)

Source: Yidu Pharma

Recently, Johnson & Johnson Innovation Pharmaceutical China announced important personnel changes: Vice President of the company,PINSDivision Head, Mature Products China Head, Hexu Zheng (Alex) Mr. [Name] will officially leave his position after serving for more than nine years, to pursue external development opportunities. His departure will be effective on2025Year12Month31Day.

He Xu Zheng has nearly28With years of in-depth experience in the pharmaceutical industry, he is a senior practitioner in the business expansion of multinational pharmaceutical companies in China and the construction of the industry ecosystem. His career history is rich and diverse. In his early years, he completed rotations in multiple departments such as business, sales, and marketing through a foreign enterprise's management trainee program, accumulating a comprehensive view of the entire chain of operations.

During his tenure at Johnson & Johnson, he served as the General Manager of Janssen in Hong Kong and Macao, China.2021Taking office as Vice President of Janssen China and Head of the Immunology and Pulmonary Arterial Hypertension Business Unit by the end of the year, deeply involved in the strategic layout of the company's core businesses.

In the field of immunology, He Xu is leading the advancement.IL-23The research and development of high-potential target drugs and their clinical translation have successfully promoted the inclusion of innovative drugs such as Guselkumab and Ustekinumab into China's national medical insurance. Meanwhile, he took the lead“Inflammatory Bowel Disease Specialty Alliance”Construction, through talent training, multi-center scientific research collaboration and other measures, effectively promotes the standardized development of grassroots diagnosis and treatment.

In the field of neuroscience, he has recently driven the establishment of a dedicated team for the antidepressant business, fully expanding the market coverage and patient services for the new mechanism-of-action drug, Eskatimibe.

As of his departure, He Xu was simultaneously responsible for Johnson & Johnson’s Innovative Pharmaceutical Business Unit in China, covering Neuroscience, Anti-Infectives, and Pulmonary Hypertension products, as well asPINSThe management responsibilities of the division have played a key role in the layout and advancement of multiple core business sectors.

Reference:EDrug Dogs